Opioid use disorder is a chronic relapsing substance use disorder involving compulsive opioid use despite harmful consequences, with elevated risk of overdose, infectious complications, and mortality.
FDA final guidance sets standards for psychedelic clinical trials. Federal agencies and states are advancing psilocybin and ibogaine research, and Eli Lilly is acquiring AtaiBeckley for $2.8 billion.
A study of over 85,000 women found that insurance coverage and healthcare access significantly affect folic acid use, increasing preventable birth defect risks. The findings support fortification efforts, while a University of Houston initiative aims to address pharmacy access barriers.
Studies reveal context-dependent genetic effects in psychiatric disorders, reassuring evidence on prenatal antidepressant use, and findings on parental depression timing, diagnostic interview reliability, and rising self-diagnosis.
Eli Lilly has launched two Phase 2 trials for brenipatide (LY3537031): RENEW-Op-1 for opioid use disorder and RENEW-Scz-1 for schizophrenia. Both are randomized, double-blind, placebo-controlled studies that are not yet recruiting as of February 2026.
Adial Pharmaceuticals completed demonstration batch production for AD04, meeting prespecified specifications and matching the prior Phase 2 dissolution profile. The step enables clinical and registration batch production for the planned Phase 3 trial.
A study of over 600,000 patients reveals GLP-1 drugs may reduce addiction across multiple substances, with 50% fewer substance-related deaths and significant reductions in overdoses and hospitalizations. The drugs work by dampening dopamine signaling in brain reward centers. Researchers are exploring broader applications for these medications beyond diabetes and obesity treatment.
Eli Lilly launched the monthly Zepbound KwikPen for obesity treatment and initiated a Phase 2 trial for opioid use disorder, while Gilead Sciences agreed to acquire Arcellx for $7.8 billion to expand its cell therapy portfolio.
Recent studies reveal significant barriers in accessing mental health care for children and maternal health services, with nearly 25% of children's mental health needs going unmet and abortion restrictions linked to increased maternal deaths.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07780097 |
TRTME: Improving Outpatient Initiation of Medication for Opioid Use Disorder Following Hospitalization |
RECRUITING | NA |
| NCT07778394 |
Personalized Addiction Treatment eHancement |
RECRUITING | NA |
| NCT07770555 |
Deep Transcranial Magnetic Stimulation for Tobacco Cessation in Adults With Opioid Use Disorder |
NOT_YET_RECRUITING | NA |
| NCT07725289 |
Clinician Practice Companion to Address Youth Substance Use |
NOT_YET_RECRUITING | NA |
| NCT07707934 |
Methadone Expansion in Detention Though the Hospital/Clinic Designation |
NOT_YET_RECRUITING | NA |
| NCT07693270 |
Identifying Biomarkers Related to Opioid Use and Pain Response Following Traumatic Injury and Surgery |
RECRUITING | |
| NCT07668635 |
Cannabis Effects on Opioid Self-Administration |
NOT_YET_RECRUITING | PHASE1 |
| NCT07632053 |
Postpartum Intervention for Mothers With Opioid Use Disorders (R33) |
RECRUITING | NA |
| NCT07631598 |
Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses |
RECRUITING | NA |
| NCT07631559 |
Pilot Study of an Adapted Partner Navigation Intervention Booster Session for Sustained Healthcare Engagement Among People Who Inject Drugs |
NOT_YET_RECRUITING | NA |
